Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2458-2463

  Lin, Chin Chung ^a   Luu, Kenneth ^a   Lourenco, David ^a   Yeh, Li Tain ^a  

^a Ribapharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; PRODRUG; RIBAMIDINE; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPECIES DIFFERENCE; ANIMAL; AREA UNDER THE CURVE; BIOTRANSFORMATION; CHEMISTRY; COMPARATIVE STUDY; FECES; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MACACA; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN; SPECIES SPECIFICITY;

EID: 0042675191     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2458-2463.2003     Document Type: Article

References (12)

1. Connor, E., S. Morrison, J. Lane, J. Oleske, R. L. Sonke, and J. Connor. 1993. Safety and tolerance and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infections. Antimicrob. Agents Chemother. 37:532-539.
2. Laskin, O. L., J. A. Longstreth, C. C. Hart, D. Scavuzzo, C. M. Connor J. D. Kalman, and R. B. Robert. 1987. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 41:546-555.
3. Lertora, J. J., A. B. Rege, J. T. Lacour, N. Ferencz, W. J. George, R. B. VanDyke, K. C. Agrawal, and N. E. Hyslop. 1991. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50:442-449.
4. 14C]ribavirin in rats and cynomolgus monkeys. Antimicrob. Agents Chemother. 47:1395-1398.
5. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Goodman Z. D. Reindollar, K. Koury, M. Ling, J. K. Albrecht, and the International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 358:958-965.
6. McHutchison, J. G., S. Gordon, E. R. Schiff, M. D. Mitchell, M. L. Shiffmann, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
7. Miller, J. P., J. Kigwana, D. G. Streeter, R. K. Robin, L. N. Simon, and J. Roboz. 1977. The relationship between the metabolism of ribairin and its proposed mechanism of action. Ann. N. Y. Acad. Sci. 284:211-229.
8. Page, T., and J. D. Connor. 1990. The metabolism of ribavirin in erythrocytes and nucleated cell. Int. J. Biochem. 22:379-383.
9. Poynard, T., P. Marcellin, S. S. Lee, C. Nieerau, G. Minuk, G. Ideo, and V. H. Bain. 1998. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C Virus. Lancet 352:1426-1432.
10. Sidwell, R. W., J. Huffman, L. B. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
11. Stephen, E., C. J. Jones, C. J. Peters, G. A. Eddy, P. S. Loizeaux, and P. B. Jahrling. 1980. Ribavirin treatment of toga-, arena-, and bunyavirus infections in subhuman primates and other laboratory species. In R. A. Smith and W. Kirkpatrick (ed.), Ribavirin: a broad spectrum antiviral agent. Academic Press, Inc., New York, N.Y.
12. Wu, J., H. Walker, J. Y. N. Lau, and Z. Hong. 2003. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 47:426-431.